Myovant Sciences to Host Fiscal First Quarter 2022 Earnings Conference Call at 5:00 p.m. EST on July 27, 2022

0

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), announced today that it will host a webcast and conference call to discuss company updates and financial results for its fiscal first quarter, ended June 30, 2022. The webcast and the conference call will take place at 5:00 p.m. Eastern Time. / 2:00 p.m. PT on July 27, 2022.

Investors and the general public can access the live webcast here. The live webcast can also be accessed by visiting the Company’s Investor Relations page on Myovant’s website at: https://investors.myovant.com/.

The webcast will be archived on the company’s website for approximately one year.

ABOUT MYOVANT SCIENCES
Myovant Sciences aspires to redefine healthcare for women and men through goal-oriented science, empowering medicines and transformative advocacy. Founded in 2016, Myovant has completed five Phase 3 clinical trials in oncology and women’s health, leading to two U.S. Food and Drug Administration (FDA) regulatory approvals for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively. Myovant has also received regulatory approvals from the European Commission (EC) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with breast cancer. advanced hormone-responsive prostate. Myovant has additional new drug applications under review with the FDA for pain associated with endometriosis and for United States Prescribing Information (USPI) updates based on safety data and efficacy from the LIBERTY phase 3 (RWS) randomized withdrawal study of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids up to two years. Myovant is also conducting a phase 3 study to assess the prevention of pregnancy in women with uterine fibroids or endometriosis. In addition, Myovant is developing MVT-602, an investigational kisspeptin-1 oligopeptide receptor agonist, which has completed a Phase 2a study in female infertility in assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is the majority shareholder of Myovant. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor contacts:
Uneek Mehra
Financial and Commercial Director
Myovant Sciences, Inc.

[email protected]

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.

[email protected]


main logo


Source link

Share.

Comments are closed.